You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

CLINICAL TRIALS PROFILE FOR VALGANCICLOVIR HYDROCHLORIDE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Valganciclovir Hydrochloride

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00002222 ↗ A Study of Valganciclovir in the Treatment of Cytomegalovirus (CMV) Retinitis in Patients With AIDS Completed Hoffmann-La Roche N/A 1969-12-31 The purpose of this study is to see if valganciclovir is a safe treatment for CMV retinitis in patients who have been treated for this condition in the past. This study also examines the effectiveness of valganciclovir in preventing the recurrence of CMV retinitis.
NCT00002377 ↗ A Comparison of Valganciclovir and Ganciclovir in the Treatment of Cytomegalovirus (CMV) of the Eyes Completed Hoffmann-La Roche Phase 3 1997-01-01 To investigate the efficacy and safety of RS-79070 when used as induction therapy in patients with newly diagnosed peripheral retinitis. To assess the effects of induction and maintenance level dosing of RS-79070 on CMV viral load, estimated by plasma CMV PCR. To assess the pharmacokinetics of ganciclovir following administration of RS-79070 in the target population.
NCT00006145 ↗ Preventing Cytomegalovirus (CMV) Organ Damage With Valganciclovir in People With HIV Completed National Institute of Allergy and Infectious Diseases (NIAID) Phase 3 2000-08-01 Cytomegalovirus (CMV) infection is a common opportunistic infection (OI) in HIV patients. The purpose of this study is to find out whether valganciclovir, an antiviral approved by the FDA for the treatment of CMV in the eye, is safe and effective in preventing CMV organ damage in people with HIV.
NCT00016068 ↗ Valganciclovir to Prevent Cytomegalovirus Infection in Patients Following Donor Stem Cell Transplantation Completed National Cancer Institute (NCI) Phase 3 2001-01-01 RATIONALE: Antivirals such as valganciclovir act against viruses and may be effective in preventing cytomegalovirus. It is not yet known if valganciclovir is effective in preventing cytomegalovirus. PURPOSE: This randomized phase III trial is studying valganciclovir to see how well it works in preventing cytomegalovirus in patients who have undergone donor stem cell transplantation.
NCT00016068 ↗ Valganciclovir to Prevent Cytomegalovirus Infection in Patients Following Donor Stem Cell Transplantation Completed Fred Hutchinson Cancer Research Center Phase 3 2001-01-01 RATIONALE: Antivirals such as valganciclovir act against viruses and may be effective in preventing cytomegalovirus. It is not yet known if valganciclovir is effective in preventing cytomegalovirus. PURPOSE: This randomized phase III trial is studying valganciclovir to see how well it works in preventing cytomegalovirus in patients who have undergone donor stem cell transplantation.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Valganciclovir Hydrochloride

Condition Name

Condition Name for Valganciclovir Hydrochloride
Intervention Trials
Cytomegalovirus Infections 18
Cytomegalovirus Infection 8
Cytomegalovirus Disease 5
HIV Infections 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Valganciclovir Hydrochloride
Intervention Trials
Cytomegalovirus Infections 45
Infections 20
Infection 16
Communicable Diseases 12
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Valganciclovir Hydrochloride

Trials by Country

Trials by Country for Valganciclovir Hydrochloride
Location Trials
United States 356
France 40
United Kingdom 33
Canada 28
Spain 25
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Valganciclovir Hydrochloride
Location Trials
California 30
New York 22
Texas 20
Pennsylvania 19
Maryland 15
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Valganciclovir Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Valganciclovir Hydrochloride
Clinical Trial Phase Trials
Phase 4 14
Phase 3 27
Phase 2/Phase 3 5
[disabled in preview] 39
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Valganciclovir Hydrochloride
Clinical Trial Phase Trials
Completed 54
Recruiting 15
Terminated 13
[disabled in preview] 16
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Valganciclovir Hydrochloride

Sponsor Name

Sponsor Name for Valganciclovir Hydrochloride
Sponsor Trials
Hoffmann-La Roche 16
National Institute of Allergy and Infectious Diseases (NIAID) 10
National Cancer Institute (NCI) 8
[disabled in preview] 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Valganciclovir Hydrochloride
Sponsor Trials
Other 127
Industry 53
NIH 23
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.